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We attempted to further characterize cutaneous serotoninergic and melatoninergic pathways evaluating the key biosynthetic enzyme
tryptophan hydroxylase (TPH). There was wide expression of TPH mRNA in whole human skin, cultured melanocytes and melanoma cells,
dermal fibroblasts, squamous cell carcinoma cells and keratinocytes. Gene expression was associated with detection of TPH immunoreactive
species by Western blotting. Characterization of the TPH immunoreactive species performed with two different antibodies showed expression
of the expected protein (55–60 kDa), and of forms with higher and lower molecular weights. This pattern of broad spectrum of TPH
expression including presumed degradation products suggests rapid turnover of the enzyme, as previously reported in mastocytoma cells. RP-
HPLC of skin extracts showed fluorescent species with the retention time of serotonin and N-acetylserotonin. Immunocytochemistry
performed in skin biopsies localized TPH immunoreactivity to normal and malignant melanocytes. We conclude that while the TPH mRNA
and protein are widely expressed in cultured normal and pathological epidermal and dermal skin cells, in vivo TPH expression is
predominantly restricted to cells of melanocytic origin.
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Accumulated evidence indicates widespread detection of
neuroendocrine elements in the skin [1]. Among these are
the small molecules of the family of neurotransmitters,
catecholamines and acetylcholine [2,3]. Most recently, we
found other family components represented by the novel
cutaneous expression of serotoninergic and melatoninergic
elements [4,5]. The supporting evidence comprised expres-
sion of the genes coding for the corresponding biosynthetic
enzymes, e.g., TPH, AANAT and HIOMT, together with the
respective enzymatic activities. Moreover, intermediate
products in the serotoninergic and melatoninergic pathways
were also identified in melanoma cells and in immortalized
keratinocytes [4,5]. Some of these findings were not unex-
pected since isolated detection of serotonin itself had been0925-4439/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
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melanoma cells [6], and serotonin metabolism to N-acetyl-
serotonin (NAS), 5-methoxytryptamine (5MTT) and possi-
bly melatonin were demonstrated in hamster skin [7–9].
The rate-limiting step in the synthesis of serotonin is
activity of tryptophan hydroxylase (TPH: EC1.14.16.4), the
enzyme converting the aromatic amino acid L-tryptophan to
hydroxytryptophan [10,11]. In humans, the TPH gene has
been located at chromosome 11, spans 29 kb and 10 of the
at least 11 exons code for the TPH protein [11–13]. The
TPH nucleotide coding sequence has 1332 bp which enc-
odes a protein of 444 amino acids (aa) with predicted
molecular weight (mw) of 51 kDa. Prostranslational mod-
ifications generate species of 50–60 kDa mw with the most
frequent form being 53 kDa [11–14]. Alternative splicing of
the gene can yield isoforms with variable spliced 5V-
untranslated regions, whereas alternative splicing of intron
11 produces a protein 22 aa longer (total of 466 aa) [12,13].
TPH monomers are organized into regulatory (N-terminal)
and catalytic (C-terminal) domains; the latter includes a
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holoenzyme of mw 220 kDa [11]. Fragment removal on
deletional studies has shown that removing fragments from
the regulatory domain of up to 106 aa will generate
truncated proteins with higher TPH activity than the un-
modified variant [11,14].
In the current study, we evaluated expression of TPH
protein in the skin, as component of a serotoninergic/
melatoninergic system. We tested whole human skin and a
variety of skin cell lines. We also localized the TPH protein
in situ in biopsies of human skin (normal and affected by
invasive melanoma).2. Materials and methods
2.1. Tissue
Human tissues consisted of non-lesional skin (23 biop-
sies from 14 patients and four large excisions from four
patients) and pathologic skin from three patients with basal
cell carcinoma and two patients involved by invasive
malignant melanoma. The samples represented skin from
face, corpus (back or chest) and upper and lower extremities
from either male or female White patients with age ranging
from 19 to 70 years old. The use of human tissues was
approved by the Karolinska Institute, Stockholm, Sweden,
and by the University of Tennessee Health Science Center
(UTHSC) Committee on Research Involving Human Sub-
jects, Memphis, TN.
2.2. Cell culture
Immortalized human epidermal melanocytes (PIG1) (gift
of Dr. C. LePoole, Loyola Medical Center) were cultured in
medium 154 (Cascade Biologicals Inc., Portland, OR)
supplemented with 5% FBS, 13 Ag/ml BPE, and 8 nM
TPA, 1 Ag/ml a-tocopherol, 0.6 ng/ml basic fibroblast
growth factor, 1 Ag/ml transferrin and 5 Ag/ml insulin (all
from Sigma) [4]. Normal human adult keratinocytes and
dermal fibroblasts were obtained from Cascade Biologics.
Keratinocytes were cultured in Cascade Epilife medium
with Ca (0.06 mM) and Epilife Defined Growth Supple-
ments (EDGS) (containing purified bovine serum albumin,
purified bovine transferrin, hydrocortisone, recombinant
human insulin-like growth factor type-1 (rhIGF-1), prosta-
glandin E2 (PGE2) and recombinant human epidermal
growth factor (rhEGF). Dermal adult fibroblasts were cul-
tured in Cascade 106 medium plus Cascade Low Serum
Supplement (containing fetal bovine serum, 2% v/v; hydro-
cortisone, 1 Ag/ml; human epidermal growth factor, 10 ng/
ml; basic fibroblast growth factor, 3 ng/ml; and heparin, 10
Ag/ml and penicillin/streptomycin/amphotericin B solution).
Immortalized HaCaT keratinocytes and human C4-1 squa-
mous cell carcinoma cells were cultured in DMEM media,
supplemented with 10% fetal calf serum (FCS) (Gibco) and1 antibiotic/antimicotic mixture containing 1000 U/ml of
penicillin, 0.1 mg/ml of streptomycin and 0.25 Ag/ml of
amphotencin B (Sigma). The SKMEL188 melanoma cell
line was cultured in Ham’s F10 medium plus 10% FBS.
Other melanoma lines established from radial growth phase
(WM 35 and SBCE2), vertical growth phase (WM 98 and
WM 1341D) and metastasis (WM 164) (gift of Dr. M.
Herlyn, Wistar Institute, Philadelphia, PA) were maintained
in DMEM plus insulin (1 Ag/ml) in the presence of 5% C02
as described previously. Culture media were routinely
supplemented with 10% fetal bovine serum (Gibco) and
antibiotics (Sigma). Media were changed every second day.
2.3. Reverse transcription polymerase chain reaction assays
(RT-PCR)
Total RNA was extracted using the Trizol isolation kit
(Gibco-BRL, Gaithersburg, MD) and the synthesis of first-
strand cDNA was performed using the Superscript pream-
plification system (Gibco-BRL) with oligo (dT) as the
primer [4].
C-terminus of human TPH was amplified by nested PCR
using following primers for the first round of amplifica
tion: forward-AGCCAGATACCTGCCATGAAC (P100), re-
verse-GCTGCAGCTCATTCATGGCAC (P101). An aliquot
of PCR mixture from the first round of amplification was
transferred to a new tube and a second round of PCR was
conducted. Primer sequences for the second round of
PCR were: forward-CCAAGAAATTGGCTTGGCTTCTC
(P106); reverse-TGCTCTTGGTGTCTTTCAGGATC
(P107). The reaction mixture (25 Al) contained 2.5 mM
MgCl2, 2.5 of each dNTP, 0.4 AM of each primer, 75 mM
Tris–HCl (pH 8.8), 20 mM (NH4)2SO4, 0.01% Tween 20
and 1.25 U of Taq polymerase (Promega). The mixture was
heated to 94 jC for 2.5 min and then amplified for 30 cycles
as specified: 94 jC for 30 s (denaturation), 65 jC for 45 s
(annealing) and 72 jC for 1 min (extension).
N-terminal region of TPH was amplified in a single
round of PCR by primers TTGAAGACAATAAGGAGAA-
CAAAG (P323) and TCTAGTTCAGATCCATACATCAG
(P324). Amplification conditions for all skin samples were
stringent and identical to those described above except that
annealing temperature was set at 56 jC.
The fragment spanning protein coding exons 1 through
10 was amplified by nested PCR. The first round of PCR
was performed with primers P323 and P101. Primers P323
and P107 were used for the second round. The mixture was
heated to 94 jC for 3 min and then amplified for 30 cycles
as specified: 94 jC for 30 s (denaturation), 55 jC for 40 s
(annealing) and 72 jC for 2 min (extension).
Amplification products were separated by agarose elec-
trophoresis and visualized by ethidium bromide staining
according to the standard protocol used in our laboratory
[4,5]. PCR products were identified and excised from the
agarose gel and purified by GFX PCR DNA and gel band
purification kit (Amersham Pharmacia Biotech). PCR prod-
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and purified by plasmid purification kit (QIAGEN). Se-
quencing was performed in the Molecular Resource Center
at the University of Tennessee HSC (Memphis) using Ap-
plied Biosystems 3100 Genetic Analyzer and BigDyek
Terminator Kit.
2.4. TPH detection by Western blot analysis
Briefly, melanoma cells were detached in Tyrode’s solu-
tion (138 mM NaCl, 2.7 mM KCl, 3.14 mM Na2PO4H2O,
2.31 mM Na3 C6 H5O7 2H2O, 0.1% D-glucose) plus 1 mM
EDTA, whereas melanocytes, keratinocytes, squamous cell
carcinoma and fibroblasts were trypsinized. Cell suspen-
sions were centrifuged at 200 g for 10 min at 4 jC. The
resulting cell pellets were washed with PBS and frozen in
 70 jC. For protein isolation, frozen cell pellets were
solubilized by pipetting into an iced buffer containing 20
mM Tris, pH 7.5, 150 mM NaCl, 15% glycerol, 1% Triton
X-100, 120 Ag/ml leupeptin, 3 AM pepstatin and 3 mM
amino-ethyl benzene sulfonyl fluoride (AEBSF). Cellular
homogenates were centrifuged at 16,000 g for 10 min at 4
jC, and the supernatants were removed and stored at  80
jC for further analysis. Separate aliquots of 5 Al were used
for protein determination by Micro protein Kit (Sigma).
Fifty micrograms of protein were loaded on 12% SDS
polyacrylamide gel, transferred to immobilion-p (poliviny-
lidene difluoride) membrane (Millipore Corp., Bedford,
MA) for 3 h at 4 jC and blocked for 4 h at room temperature
in 5% nonfat powdered milk in TBST (50 mM Tris, pH 7.5,
150 mM NaCl, 0.01% Tween-20). Immunodetections of the
TPH protein were performed after independent overnight
incubations at 4 jC (dilution 1:1000) with either affinity-
purified polyclonal rabbit anti-TPH antibody (dilution
1:1000; lot #19030270) or sheep anti-TPH primary antibody
(dilution 1:500; lot #22010680) as the primary antibody
(Chemicon, Temecula CA). The next day, membranes were
washed twice in TBST for 10 min. Goat anti-rabbit IgG or
bovine anti-sheep IgG coupled to horseradish peroxidase
were respectively used as a secondary antibody (dilution
1:4000, 1 h) (Santa Cruz Biotechnology). Membranes were
washed twice in TBST and once in TBS. Bands were
visualized by ECL reagent according to the manufacturer’s
instructions (Amersham Pharmacia Biotech).
2.5. Immunohistochemistry
Paraffin sections were deparaffinized, rehydrated and
processed in citrate buffer for antigen retrieval by microwave
treatment. After hydrogen peroxide quenching for endoge-
nous peroxidase activity, and blocking of nonspecific binding
with normal swine serum (Dako A/S, Glosterup, Denmark),
the sections were incubated overnight at 4 jC with primary
polyclonal antibody (1:200; rabbit anti-TPH; Chemicon
International Inc.). The tissue sections were then washed
and treated with biotinylated swine anti-rabbit serum (1:200;Dako). After washing, the sections were incubated with
avidin biotin–peroxidase complex (Vector Laboratories),
washed and visualized with 3-amino-9-ethyl-carbazole as
enzyme substrate, and hematoxylin as counterstain.
Indirect immunofluorescence stains were performed
according to standard protocols [6]. Briefly, serial cryostat
sections (14 um) were obtained and processed as described
below. Rabbit polyclonal antibodies to TPH (1:200; Chem-
icon), mouse monoclonal antibodies to HLA-DR (to stain
dendritic cells of immune origin) (1:200; Dako) mouse
monoclonal antibodies to melanocyte-associated antigen
NKI-beteb (1:80; Sanbio BV, Am Uden, the Netherlands)
were used for the indirect immunofluorescence technique, in
either single- or double-labeling experiments. Tissue sec-
tions, kept in a humid atmosphere, were incubated overnight
at 4 jC, with the abovementioned antisera; after rinsing in
phosphate-buffered saline, sections were incubated for an
additional 30 min at 37 jC in tetramethylrhodamine-iso-
thiocyanate (TRITC)-conjugated donkey anti-rabbit IgG
(1:160; Jackson, West Grove, PA), or fluorescein-isothio-
cyanate (FITC)-conjugated donkey anti-mouse IgG (1:160,
Jackson), rinsed and mounted. All antisera were diluted in
0.3% Triton X-100. A control test for nonspecific binding of
the conjugated antibodies was represented by omission of
the primary antibody. To test for secondary antiserum cross-
reaction in the double-staining experiments, sections were
incubated with the rabbit antibodies, and by FITC-conju-
gated donkey anti-mouse IgG and mouse antibodies fol-
lowed by TRITC-conjugated donkey anti-rabbit IgG. Visual
inspection and photography were performed with a Nikon
Microphot-FXA equipped with dark-field optics.
2.6. Reverse phase high performance liquid
chromatography (RP-HPLC)
A fluorimetric detection system for serotonin was used as
described previously [4]. Briefly, the skin was processed by
homogenization and the centrifuged supernatants subjected
to HPLC in a system equipped with a Novapak C18 reverse-
phase column (100 5 mm, i.d.) and fluorometric detector
(Waters). Detector calibration was set at excitation and
emission wavelengths of 285 and 360 nm, respectively.
Elution was carried out isocratically at ambient temperature
with a flow rate of 1.5 ml/min for the different mobile phases
according to the amine substrate being evaluated. The mobile
phase contained 4 mM sodium 1-octanesulfonate as ion-
pairing agent, 50 mM ammonium formate (pH 4.0) versus
methanol (80:20) for detection of serotonin. The elution peak
of serotonin was identified by retention time, and the identity
verified by co-elution with the authentic standard.3. Results and discussion
When using primers located at exons coding for the C-
terminal (catalytic domain) of TPH (Fig. 1A) we detected
AFig. 1. RT-PCR of human TPH. (A) Structure of the coding region of the human TPH gene. Open boxes and corresponding arbitrary numbering of the exons (1
to 10) relate only to the coding region. Note that the TPH gene is known to contain at least one more exon in the nontranslated region [12]. Arrows indicate
primer positions. (B) RT-PCR of the catalytic domain. DNA ladder, 1; human pituitary, 2; adrenal gland, 3; myometrium, 4; human skin, 5; melanoma
SKMEL-88, 6; basal cell skin carcinomas, 7–9; HaCaT, 10; RT-control, 11. (C) RT-PCR of the regulatory domain: DNA ladder, 1,8; immortalized
melanocytes, 2; melanomas SBCE2, 3; WM35, 4; WM164, 5; WM1341D, 6; WM98, 7. (D) Long-range PCR of human TPH: HaCaT keratinocytes, 1;
melanomas SBCE2, 2; WM35, 3; WM98, 4; WM1341, 5. On the left, position and size (bp) of the DNA ladder are listed.
Table 1













+ + + +
WM35
melanoma cells
+ + + +
WM164
melanoma cells
+ + + ND
SKMEL-188
melanoma cells
+ +  
WM1341
melanoma cells
+ + + +
WM98 + + + +
PIG-1 melanocytes + + + ND
Dermal fibroblasts + + + ND
C4-1 squamous
cell carcinoma
+ + + ND
HaCaT
keratinocytes
+  + +
Adult epidermal
keratinocytes
+ + + ND
The results represent a summary of several independent experiments.
Present (+); absent ( ); not done (ND).
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tured epidermal and follicular keratinocytes and melano-
cytes, dermal and hair papilla fibroblasts with exception of
immortalized HaCaT cells [4]. We repeated these experi-
ments and found similar expression in whole normal and
pathologic skin, cultured squamous cell carcinoma C4-1 and
melanoma lines but not in HaCaT keratinocytes (Fig. 1B).
TPH RNAwas also detected in non-skin tissues represented
by pituitary, adrenal gland and myometrium. Re-testing of
the original samples with primers located instead at exons
coding for the N-terminus (regulatory domain) of the
enzyme showed almost uniform expression of TPH mRNA
(Table 1; representative panel of several experiments is
shown in Fig. 1C), which this time included immortalized
HaCaT keratinocytes (not shown); the sole exception was
represented by the single melanoma cell line (SKMEL-188)
(Table 1). In addition, in four melanoma specimens, we also
amplified the 1245-bp-long fragment of TPH mRNA span-
ning the coding exons 1 through 10 that corresponded to the
published sequence of human TPH (Fig. 1D; GenBank
accession #X52836). This full-length transcript was also
detected in the HaCaT cells (Fig. 1D, lane 1). However, the
observed sequence in HaCaT keratinocytes contained sev-
eral mutations (GenBank accession #AY196344 and
AY196345) leading to amino acid substitutions: one in the
regulatory domain (F77L) and one in the catalytic domain
(F377P). The presence of the above mutations in the HaCaT
TPH sequence together with technical problems with the
detection of C-terminal TPH mRNA in the same cell line
suggest an additional mutation in the binding site of primer
P101, thus providing an explanation for our failure toamplify the C-terminus in these cells. The additional 464-
bp-long band shown in Fig. 1D represents an aberrantly
spliced form of TPH (GenBank accession #AY196346).
Since this form contains a stop codon, it is unlikely to have
significant enzymatic activity. Thus, skin cells express both
Fig. 2. Detection of TPH immunoreactive proteins by Western blot analysis.
(A) Immunodetection using sheep anti-TPH antibodies (upper panel).
Lower panel presents blots incubated with secondary antibody only. Mw
marker (kDa), on the right; HaCaT immortalized keratinocytes, 1; normal
epidermal keratinocytes, 2; C4-1 squamous cell carcinoma cells, 3; dermal
fibroblasts, 4; immortalized melanocytes, 5; melanoma SKMEL188, 6; and
WM164, 7. Arrow indicates TPH-like immunoreactivity of 55–60 kDa. (B)
Immunodetection using rabbit anti-TPH antibodies: HaCaT immortalized
keratinocytes, 1; normal epidermal keratinocytes, 2; immortalized melano-
cytes, 3; C4-1 squamous cell carcinoma cells, 4; dermal fibroblasts, 5;
melanoma WM35, 6; human skin, 7. Arrow indicates TPH-like
immunoreactivity of 55–60 kDa; while arrowhead indicates TPH-like
immunoreactivity of approximately 48 kDa.
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least in HaCaT keratinocytes, mutations in the regulatory
and catalytic domains are the most likely cause of unde-
tectable enzymatic activity in this cell line.
Several independent Western blotting experiments of
cytoplasmic extracts from skin homogenates and cultured
skin cells identified proteins specifically detected with two
different anti-TPH antibodies (rabbit and sheep) (Fig. 2)
(Table 1). Thus, the specific 55–60 kDa protein was
visualized after treatment with anti-TPH sheep antibodies
(arrow) in normal epidermal keratinocytes, immortalized
HaCaT keratinocytes, squamous cell carcinoma, immortal-
ized melanocytes, dermal fibroblasts and melanoma cells
(Fig. 2A, upper panel); corresponding bands were absent in
control samples incubated only with secondary antibodies
(Fig. 2A, lower panel). Sheep anti-TPH antibodies also
brought out additional proteins of higher (85–90 kDa)
and lower (33–35, 27 and 20 kDa) mw (Fig. 2A); whereas
rabbit anti-TPH antibodies emphasized TPH-like antigens of
lower mw (33–35 and 20 kDa) as prominent species, as
well as low lower levels of 55–60 kDa and 80–90 kDa mw
species (Fig. 2B). Thus, the protein of expected size, 55–60
kDa, was detected by this antibody in normal epidermal
keratinocytes, immortalized HaCaT keratinocytes, squa-
mous cell carcinoma, immortalized melanocytes and mela-
noma cells. In the case of dermal fibroblasts, the discrepancy
between results with sheep and rabbit antibodies is probably
explained by differences in the epitope(s) recognized by
respective anti-TPH antibodies or by rapid degradation of
the enzyme. Prominent expression of the 48 kDa protein
was found in whole human skin after treatment with the
rabbit antibody (Fig. 2B), and that also showed an 80 kDa
protein in SKMEL188 melanoma (not shown). Thus, using
two different antibodies, we detected by Western blots THP
immunoreactivities of expected size together with higher or
lower mw forms in a variety of skin samples.
The mw of newly translated TPH changes after post-
translational modification [11]. This is consistent with our
detection of the 48 kDa form as the prominent species in
skin extracts, and of a protein of 55–60 kDa in normal and
malignant skin cells (Fig. 2). Variants with higher and lower
mw (TPH degradation products) have also been described
[16]. For example, in mastocytoma cells ubiquitination of
TPH can generate higher mw species of 80–93 kDa [16].
Further, studies in mastocytoma cells have shown that TPH
undergoes very fast turnover driven by proteasomes leading
to the degradation of native TPH into species of lower mw
[17]. Similar mechanisms may operate in skin cells, where
the appearance of high mw TPH-like species could repre-
sent ubiquitinated TPH, whereas low mw TPH-like species
could represent rapid degradation (Fig. 2). In vitro experi-
ments, of deletion of different portions of the human TPH
gene have shown more enzymatic activity in a protein
lacking the N-terminus regulatory domain with mw of
approximately 35 kDa, than in the full-length form
[11,15]. Thus, the 35 kDa species we detected in many skinsamples could represent C-terminus products of TPH catab-
olism still having the catalytic domain; and the 27 and 20
kDa species could represent either proteolytically cleaved
N-terminus TPH regulatory domain or a product of further
degradation of 35 kDa protein(s). Since alternative splicing
Fig. 4. Representative HPLC chromatograms of the skin. Endogenous
fluorescence is present at the elution position of standards corresponding to
NAS (1) and serotonin (2).
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diversity in TPH-like immunoreactivity mw could addition-
ally be due to translation of alternatively spliced TPH
mRNA.
Immunohistochemical analysis of paraffin-embedded
pathologic skin showed intense TPH labeling of normal
melanocytes in the basal layer as well as in the spinous and
granular layers. Strong stain for TPH was also seen in
melanoma cells, whether intraepidermally or in the dermal
(invasive) compartment (Fig. 3A). TPH immunoreactive
cells of normal skin were distributed sparsely throughout
the stratum basale separated by three to five epidermal basal
cells in between (not shown). The TPH signal was further
localized to the cellular cytoplasm compartment. Interest-
ingly, the cells staining positive appeared dendritic in nature,
with rich cytoplasm and short, thin processes that also
stained with NKI-beteb antibodies. We identified those cells
as melanocytes, which was confirmed by their double
labeling with antibodies against TPH and NKI-beteb (Fig.
3B). Potentially all skin cells can express TPH (cf. cellFig. 3. Detection in situ of TPH-positive cells in the human skin. (A)
Immunohistochemistry of biopsy from skin involved with melanoma.
Arrows indicate TPH-immunoreactive cells in both the epidermis and
dermis. Bar indicates 50 Am. (B) Immunofluorescence double-staining in
normal human skin. Red: cells positive for NKI-beteb antigen; green: cells
positive for TPH; orange: double-labeled cells. Singe arrow indicates
TPH-immunoreactive cells. Double arrows indicate double-labeled NKI-
beteb and TPH-positive cells in the stratum basale of the epidermis. Bar
indicates 50 Am.culture experiments), nevertheless, in human skin, in vivo
TPH is expressed predominantly in normal and malignant
melanocytes. Whether TPH could represent a potential
therapeutic target in melanoma and/or pigmented disorders
is certainly an interesting possibility, especially when con-
sidering that it represents a first regulatory point of seroto-
ninergic and melatoninergic systems.
The co-localization of the enzyme (present study) with
the serotonin antigen [6] implies active metabolism in situ,
from tryptophan to serotonin. Indeed, RP-HPLC analysis of
human skin extracts showed clear fluorescent peaks that
eluted at retention times corresponding to the serotonin and
NAS standards, suggesting cutaneous metabolism of tryp-
tophan to serotonin and NAS, with storage of both amines
(Fig. 4). These results are also consistent with our previous
studies in cultured melanoma cells, where we not only
detected TPH activity but also identified OH-Trp, serotonin
and NAS by LC/MS [5].
Serotonin has a number of effects in the skin that include
pro-edema, vasodilatory, pruritogenic and proinflammatory
activities, as well as growth factor actions. Since these are
common components of a number of skin disorders, it is
possible that locally produced serotonin could participate in
their pathogenesis. Serotonin local synthesis and cellular
localization could thus become of great importance in the
diagnosis and management of cutaneous pathology.
In the current study, we show TPH gene and protein
expression in the human skin and its cellular localization
with predominance to normal and malignant melanocytes.
Western blot analysis and RT-PCR tests suggest alternative
splicing of the gene and potentially rapid turnover of the
enzyme in skin cells cultured in vitro. Thus, cultured skin
cells represent excellent models for the study of differential
expression of TPH isoforms, as well as for the cellular
processing of the protein product. These findings strongly
support the full expression of a novel serotoninergic system
in the skin. This system appears to be secluded in vivo to a
A. Slominski et al. / Biochimica et Biophysica Acta 1639 (2003) 80–8686tightly regulated cutaneous environment at a highly com-
partmentalized level.
In conclusion, the enzyme TPH is widely expressed in
cultured skin cells; in vivo, it is instead localized, predom-
inantly to normal and malignant melanocytes.Acknowledgements
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